NeoGenomics (NASDAQ:NEO) is a specialized laboratory focused on genetic testing for cancer diagnosis, prognosis, and treatment planning. The company operates through a network of labs across the United States, offering a wide range of testing services, including cytogenetics, fluorescence in-situ hybridization (FISH), flow cytometry, immunohistochemistry, molecular genetics, and next-generation sequencing. NeoGenomics aims to support personalizing cancer care through its comprehensive testing solutions, working closely with pathologists, oncologists, academic centers, and pharmaceutical companies. Their projects often involve developing new tests and technologies to stay at the forefront of precision medicine in oncology, with the objective of enhancing patient outcomes through tailored treatment approaches.